Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Domchek

Showing results (141-150 of 361) with videos related to

Pageof 37
Sort By:
Genetics in Medicine Open|February 3, 2025
Pilot implementation study of a default genetic referral process for patients with early-onset colorectal cancerKelsey S Lau-Min, Shavon Rochester, Megan Grabill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2023
The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on RucaparibTimothy J Brown, Arielle Yablonovitch, Jacob E Till, et al.
Journal of Genetic Counseling|October 17, 2022
Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriersDanielle B McKenna, Pauleen Sanchez, Jacquelyn Powers, et al.
Breast Cancer Research and Treatment|June 11, 2008
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Andrew J Deans, David Duffy, et al.
Nature Communications|June 8, 2023
Identification of BRCA1/2 mutation female carriers using circulating microRNA profilesKevin Elias, Urszula Smyczynska, Konrad Stawiski, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safetyRebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
Clinical Genetics|September 12, 2022
Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthoodKara N Maxwell, Vishal Patel, Kevin T Nead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|July 23, 2025
What Happens After Menopause (WHAM)? A Progress Report of a Prospective Controlled Study of Women After Pre-Menopausal Risk-Reducing Bilateral Salpingo-OophorectomySarah A L Price, Pauline M Maki, Samar R El Khoudary, et al.
Pageof 37

Showing results (141-150 of 361) with videos related to

Sort By:
Pageof 37
Genetics in Medicine Open|February 3, 2025
Pilot implementation study of a default genetic referral process for patients with early-onset colorectal cancerKelsey S Lau-Min, Shavon Rochester, Megan Grabill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2023
The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on RucaparibTimothy J Brown, Arielle Yablonovitch, Jacob E Till, et al.
Journal of Genetic Counseling|October 17, 2022
Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriersDanielle B McKenna, Pauleen Sanchez, Jacquelyn Powers, et al.
Breast Cancer Research and Treatment|June 11, 2008
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Andrew J Deans, David Duffy, et al.
Nature Communications|June 8, 2023
Identification of BRCA1/2 mutation female carriers using circulating microRNA profilesKevin Elias, Urszula Smyczynska, Konrad Stawiski, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safetyRebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2011
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancerSusan M Domchek, Gillian Mitchell, Geoffrey J Lindeman, et al.
Clinical Genetics|September 12, 2022
Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthoodKara N Maxwell, Vishal Patel, Kevin T Nead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|July 23, 2025
What Happens After Menopause (WHAM)? A Progress Report of a Prospective Controlled Study of Women After Pre-Menopausal Risk-Reducing Bilateral Salpingo-OophorectomySarah A L Price, Pauline M Maki, Samar R El Khoudary, et al.
Pageof 37